Drug Profile
Integrin inhibitor - Epigen Biosciences
Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Epigen Biosciences
- Class Antifibrotics; Small molecules
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic nephropathies
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Diabetic-nephropathies in USA
- 23 May 2018 Preclinical trials in Diabetic nephropathies in USA (unspecified route) prior to May 2018